Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-22
2008-01-22
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S046000, C546S044000, C546S074000, C544S056000, C544S125000, C544S361000, C514S289000, C514S254080, C514S232800, C514S228200
Reexamination Certificate
active
07320984
ABSTRACT:
The invention provides a morphinan derivative of the Formula (I):wherein R1is methyl, cyclopropylmethyl or the like; R2and R3are hydroxy, methoxy, acetoxy or the like; both Y and Z are valence bonds, —C(═O)— or the like; X is C2-C5carbon chain (one of the carbon atoms may be substituted by oxygen, sulfur or nitrogen) constituting a part of the ring structure, or the like; (R4)k is substituted or non-substituted benzene fused ring, carbonyl group or the like; R9is hydrogen or the like; R10and R11are bound to represent —O—, or the like, and R6is hydrogen or the like or a pharmaceutically acceptable acid addition salt thereof. The invention also provides a therapeutic or prophylactic agent for urinary frequency or urinary incontinence, comprising as an effective ingredient the morphinan derivative or the pharmaceutically acceptable acid addition salt thereof; a method for therapy or prophylaxis of the diseases.
REFERENCES:
patent: 3318885 (1967-05-01), Brown et al.
patent: 0 846 694 (1998-06-01), None
patent: 11-501627 (1999-02-01), None
patent: WO 95/03308 (1995-02-01), None
patent: WO 01/05795 (2001-01-01), None
patent: WO 02/080918 (2002-10-01), None
Simon, C. et al.: Stereoselective synthesis of beta-naltrexol, beta-naloxol, beta-naloxamine, beta-naltrexamine and related compounds. Tetrahedron, vol. 50, pp. 9757-9768, 1994.
Csaba Simon et al, “Stereoselective Synthesis of β-Naltrexol, β -Naloxol, β -Naloxamine, β -Naltrexamine and Related Compounds by the Application of the Mitsunobu Reaction”,Tetrahedron, vol. 50, No. 32, pp. 9757-9768, 1994.
László Szilágyi et al, “Substituent-Dependent Conformational Changes in 6 β -Substituted Codeine Derivatives”,Magnetic Resonance in Chemistry, vol. 30, pp. 552-557 (1992).
Csaba Simon et al, “Mitsunobu Reaction for Morphine Compounds. Preparation of 6β-Aminomorphine and Codeine Derivatives”,Synthetic Communications, vol. 22, No. 6, pp. 913-921 (1992).
L. M. Sayre, et al, “Design and Synthesis of Naltrexone-Derived Affinity Labels with Nonequilibrium Opioid Agonist and Antagonist Activities. Evidence for the Existence of Different μ Receptor Subtypes in Different Tissues”,Journal of Medicinal Chemistry. vol. 27, No. 10, pp. 1325-1335 (1984).
Issei Iwai, “14-Hydroxy-6.alpha.-aminodihydrocorsides”, retrieved from STN, Abstract and JP 41 018826 B4 (Sankyo Co., Ltd.) (Oct. 31, 1964).
Issei Iwai, “6-Aminodihydromorphides”, retrieved from STN, Abstract and JP 41 018824 B4 (Sankyo Co., Ltd) (Oct. 31, 1964).
Isao Seki, “Morpholine alkaloids. IX. Aminomorphide compounds. 1. The formation of enamines and the additionof amine to .alpha.,.beta.-unsaturated ketones”, retrieved from STN, Abstract and Yagugaku Zasshi, 84(7), 621-5 (1964).
Isao Seki, “Morpholine alkaloids. X. Aminomorpholide compounds. 2. The reduction of enamines and the catalytic reductive amination of C-6 ketones”, retrieved from STN, Abstract and Yagugaku Zasshi, 84(7), 626-31 (1964).
Isao Seki, “Morpholine alkaloids. XI. Aminomorphde compounds. 3. The steric aspects of the amino group”, retrieved from STN, Abstract and Yagugaku Zasshi, 84(7) (1964).
A. G. Hayes et al, “Evaluation of the Receptor Selectivities of Opioid Drugs by Investigating the Block of Their Effect on Urine Output by β-Funaltrexamine”,Journal of Pharmacology and Experimental Therapeutics, vol. 240, No. 3, pp. 984-988 (1987).
A Dray et al., “Morphine and the Centrally-Mediated Inhibition of Urinary Bladder Motility in the Rat”,Brain Research. vol. 297, No. 1, pp. 191-195 (1984)).
A. Dray et al., “Opioids and Central Inhibition of Urinary Bladder Motility”,European Journal of Pharmacology, vol. 98, No. 1, pp. 155-156 (1984)).
Fujimura Morihiro
Izumimoto Naoki
Kawai Koji
Kawamura Kuniaki
Komagata Toshikazu
Aulakh Charanjit S.
DLA Piper (US) LLP
Toray Industries Inc.
LandOfFree
Remedies or preventives for urinary frequency or urinary... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Remedies or preventives for urinary frequency or urinary..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Remedies or preventives for urinary frequency or urinary... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2796158